Rantin 150 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Seema pharmaceuticals ltd |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients
Pharmacology
Blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Dosage & Administration
- 150 mg twice daily for active duodenal and benign gastric ulcer
- 150 mg twice daily for reflux oesophagitis
- 150 mg 3 times daily for Zollinger Ellison syndrome
- 150 mg twice daily for episodic dyspepsia
- 150 mg at night for maintenance
- 2-4 mg/kg twice daily for children with peptic ulcer
- Oral or intravenous administration for haemorrhage prophylaxis
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide. Minimally inhibits hepatic metabolism of certain drugs, may alter absorption of pH-dependent drugs, and may reduce bioavailability with antacids.
Contraindications
Patients hypersensitive to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Crosses the placenta
- No evidence of impaired fertility or harm to the foetus
- Excreted in human breast milk
Precautions & Warnings
Given in reduced dosage to patients with impaired renal and hepatic function
Use in Special Populations
Similar ulcer healing rates in elderly patients as in younger patients with no significant difference in adverse effects
Overdose Effects
No particular problems are expected following overdosage. Symptomatic and supportive therapy should be given as appropriate.
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Ranitidine 50 mg diluted to a concentration ≤2.5 mg/mL for slow IV inj
- Ranitidine 50 mg diluted to a concentration ≤0.5 mg/mL for intermittent slow IV infusion
- Ranitidine 150 mg diluted in 250 mL of dextrose 5% or NaCl 0.9% for continuous IV infusion
Storage Conditions
Store in a cool and dry place, protect from light